Literature DB >> 10087388

Association of health-related quality of life and benign prostatic enlargement.

C J Girman1, S J Jacobsen, T Rhodes, H A Guess, R O Roberts, M M Lieber.   

Abstract

OBJECTIVE: To investigate the association of benign prostatic enlargement and health-related quality of life (HRQoL) assessed by validated questionnaires.
METHOD: Randomly selected men (n = 471) aged 40-79 years from Olmsted County, Minn. (USA) without prior prostate surgery or prostate cancer had a full urologic workup, including transrectal ultrasonography, in addition to completing questionnaires soliciting information about urinary symptom frequency, bother, degree of interference with daily activities and other measures of HRQoL.
RESULTS: Disease-specific HRQoL was worse in older men, and men with more severe symptoms. Age-adjusted mean scores for symptom severity, bother and activity interference were about 50% worse for men with enlarged prostates (volume > 40 cm3). After adjusting for age, men with enlarged prostates were nearly 3 times (95% CI 1.6, 5.1) as likely to have moderate to severe symptoms, and about twice as likely to have bother (odds ratio 2.4; 95% CI 1.3, 4.2) or activity interference (odds ratio 1.8; 95% CI 1. 0, 3.2) relative to men with smaller prostates.
CONCLUSION: HRQoL measures are worse in men who are older and, after adjusting for age, in men with increased urinary symptom frequency and enlarged prostate. The broader spectrum of patients provided by the community-based random sampling allows elucidation of these important relationships.

Entities:  

Mesh:

Year:  1999        PMID: 10087388     DOI: 10.1159/000019861

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

1.  How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)?

Authors:  J Haltbakk; B R Hanestad; S Hunskaar
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

2.  Sexual Function and alpha-Blockers.

Authors:  Kevin T McVary
Journal:  Rev Urol       Date:  2005

3.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

4.  Associations between modest weight changes and onset and progression of lower urinary tract symptoms in two population-based cohorts.

Authors:  Jennifer L St Sauver; Aruna V Sarma; John M Hollingsworth; Debra J Jacobson; Michaela E McGree; Rodney L Dunn; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2011-06-15       Impact factor: 2.649

Review 5.  Sexual dysfunction in the patient with prostatitis.

Authors:  Alexander Müller; John P Mulhall
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 6.  Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.

Authors:  J E Batista-Miranda; M D Diez; P A Bertrán; H Villavicencio
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Benign prostatic hyperplasia: an overview.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2005

8.  Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms.

Authors:  Jennifer L St Sauver; Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; Ajay Nehra; Veronique L Roger; Michael M Lieber
Journal:  BJU Int       Date:  2010-08-26       Impact factor: 5.588

Review 9.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

Review 10.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.